Abstract

  Encephalitis is a condition characterized by inflammation of brain parenchyma leading to symptoms like acute fever, seizures, altered mental status, focal neurological deficits, neurological disability post recovery and even death. Infectious cause may comprise of virus, bacteria, fungus or parasitic agents. Viral causes account for the largest proportion of cases but encephalitis caused by microbes other than virus are frequently reported in immunocompetent individuals. This review article focuses on diagnosis, management and prognosis of acute or subacute infectious causes of encephalitis. Role of cerebrospinal fluid studies, MRI, novel diagnostic methods like next generation sequencing are also studied.

Keywords: Encephalitis; Infection; Immunocompetent; Diagnosis; Management; Prognosis; Next Generation Sequencing

References

1. Venkatesan A., et al. “Case definitions, diagnostic algorithms, and priorities in encephalitis:consensus statement of the International Encephalitis Consortium”. Clinical Infectious Diseases 57 (2013): 1114-1128. 
2. Graus F., et al. “A clinical approach to diagnosis of autoimmune encephalitis”. The Lancet Neurology 15 (2016): 391–404. 
3. Venkatesan A and Geocadin RG. “Diagnosis and management of acute encephalitis: a practical approach”. Neurology Clinical Practice 4 (2014): 206–215. 
4. Solomon T., et al. “Management of suspected viral encephalitis in adults —Association of British Neurologists and British Infection Association National Guidelines”. Journal of Infection 64 (2012): 347–373. 
5. Geschwind MD., et al. “Rapidly progressive dementia”. Annals of Neurology 64 (2008): 97–108. 
6. Granerod J., et al. “Challenge of the unknown. A systematic review of acute encephalitis in non-outbreak situations”. Neurology 75 (2010): 924–932. 
7. Granerod J., et al. “New estimates of incidence of encephalitis in England”. Emerging Infectious Diseases Journal 19 (2013): 1455–1462. 
8. George BP., et al. “Encephalitis hospitalization rates and inpatient mortality in the United States, 2000–2010”. PLoS One 9 (2014): e104169. 
9. Boucher A., et al. “Epidemiology of infectious encephalitis causes in 2016”. Médecine et Maladies Infectieuses 47 (2017): 221–35. 
10. Vora NM., et al. “Burden of encephalitis-associated hospitalizations in the United States, 1998-2010”. Neurology 82 (2014): 443-451. 
11. Granerod J., et al. “Causes of encephalitis and differences in their clinical presentations in England:a multicentre, population-based prospective study”. The Lancet Infectious Diseases 10 (2010): 835–844. 
12. Montgomery RR. “Age-related alterations in immune responses to West Nile virus infection”. Clinical and Experimental Immunology 187 (2017): 26-34. 
13. Moraru M., et al. “Host genetic factors in susceptibility to herpes simplex type 1 virus infection:contribution of polymorphic genes at the interface of innate and adaptive immunity”. The Journal of Immunology 188 (2012): 4412-4420. 
14. Taylor KG., et al. “Age-dependent myeloid dendritic cell responses mediate resistance to La Crosse virus-induced neurological disease”. Journal of Virology 88 (2014): 11070-11079. 
15. Long D., et al. “Identification of genetic variants associated with susceptibility to West Nile virus neuroinvasive disease”. Genes and Immunity 17 (2016): 298-304.
16. Crosslin DR., et al. “Genetic variation in the HLA region is associated with susceptibility to herpes zoster”. Genes and Immunity 16 (2015): 1-7. 
17. Qian F., et al. “Immune markers associated with host susceptibility to infection with West Nile virus”. Viral Immunology 27 (2014): 39-47. 
18. Qian F., et al. “Systems immunology reveals markers of susceptibility to West Nile virus infection”. Clinical and Vaccine Immunology 22 (2015): 6-16. 
19. Ignatieva EV., et al. “A database of human genes and a gene network involved in response to tick-borne encephalitis virus infection”. BMC Evolutionary Biology 17 (2017): 259. 
20. Mickiene A., et al. “Polymorphisms in chemokine receptor 5 and Toll-like receptor 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian population”. PLoS One 9.9 (2014): e106798. 
21. Lim JK., et al. “CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission”. The Journal of Infectious Diseases 201 (2010): 178-185. 
22. Mørk N., et al. “Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis”. Genes and Immunity 16 (2015): 552-566. 
23. Verma R and Bharti K. “Toll like receptor 3 and viral infections of nervous system”. Journal of the Neurological Sciences 372 (2017): 40-48. 
24. Sironi M., et al. “TLR3 mutations in adult patients with herpes simplex virus and varicella-zoster virus encephalitis”. The Journal of Infectious Diseases 215 (2017): 1430-1434. 
25. Lim JK., et al. “Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man”. PLoS Pathogens 5.2 (2009): e1000321. 
26. Chow FC., et al. “Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics”. Clinical Infectious Diseases 60 (2015): 1377–1383. 
27. Ooi MH., et al. “Clinical features, diagnosis, and management of enterovirus 71”. The Lancet Neurology 9 (2010): 1097–1105. 
28. Solomon T., et al. “Poliomyelitis-like illness due to Japanese encephalitis virus”. Lancet 351 (1998): 1094–1097. 
29. Steiner I., et al. “Viral meningoencephalitis: a review of diagnostic methods and guidelines for management”. European Journal of Neurology 17.8 (2010): 999-1009. 
30. Tunkel AR., et al. “The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America”. Clinical Infectious Diseases 47 (2008): 303-327. 
31. Whitley RJ., et al. “Herpes simplex encephalitis”. Journal of the American Medicine Association 247 (1982): 317-20. 
32. Glaser CA., et al. “Beyond viruses: clinical profiles and etiologies associated with encephalitis”. Clinical Infectious Diseases 43 (2006): 1565-1577. 
33. Beattie GC., et al. “Encephalitis with thalamic and basal ganglia abnormalities: etiologies, neuroimaging, and potential role of respiratory viruses”. Clinical Infectious Diseases 56 (2013): 825-832. 
34. Sili U., et al. “Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 106 adult patients”. Journal of Clinical Virology 60 (2014): 112-118. 
35. Raschilas F., et al. “Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study”. Clinical Infectious Diseases 35 (2002): 254–260. 
36. Bradshaw MJ and Venkatesan A. “Herpes simplex virus-1 encephalitis in adults: pathophysiology, diagnosis, and management”. Neurotherapeutics 13 (2016): 493–508. 
37. Murray WJ and Kazacos KR. “Raccoon roundworm encephalitis”. Clinical Infectious Diseases 39 (2004): 1484–1492. 
38. Kaewpoowat Q., et al. “Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes”. Infection 44 (2016): 337–345. 
39. David S and Abraham AM. “Epidemiological and clinical aspects on West Nile virus, a globally emerging pathogen”. Infectious Diseases 48 (2016): 571–586. 
40. Soares CN., et al. “Fatal encephalitis associated with Zika virus infection in an adult”. Journal of Clinical Virology 83 (2016): 63–65. 
41. Armstrong RW and Fung PC. “Brainstem encephalitis (rhombencephalitis) due to Listeria monocytogenes: case report and review”. Clinical Infectious Diseases 16 (1993): 689–702. 
42. Lipsky BA., et al. “Factors affecting the clinical value of microscopy for acid-fast bacilli”. Reviews of Infectious Diseases 6 (1984): 214–222. 
43. Mai NT and Thwaites GE. “Recent advances in the diagnosis and management of tuberculous meningitis”. Current Opinion in Infectious Diseases 30 (2017): 123–128. 
44. Bahr NC., et al. “Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study”. The Lancet Infectious Diseases 18 (2018): 68–75. 
45. Lyons JL and Zhang SX. “Current laboratory approaches to diagnosis of CNS fungal infections”. Future Microbiology 11 (2016): 175–177. 
46. Whitley RJ., et al. “Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group”. The Journal of the American Medical Association 262 (1989): 234–239. 
47. Glaser CA and Venkatesan A. In: Scheld WWR, Marra CM, eds. Infections of the Central Nervous System. Philadelphia: Wolters Kluwer Health, (2014): 84–111. 
48. Wilson ME., et al. “Fever in returned travelers: results from the GeoSentinel Surveillance Network”. Clinical Infectious Diseases 44 (2007): 1560–1568. 
49. Czupryna P., et al. “Comparison of hyponatremia and SIADH frequency in patients with tick borne encephalitis and meningitis of other origin”. Scandinavian Journal of Clinical and Laboratory Investigation 76 (2016): 159–164. 
50. Goenka A., et al. “Neurological manifestations of influenza infection in children and adults: results of a National British Surveillance Study”. Clinical Infectious Diseases 58 (2014): 775–784. 
51. Leber AL., et al. “Multicenter evaluation of biofire filmarray meningitis/encephalitis panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens”. Journal of Clinical Microbiology 54 (2016): 2251–2261. 
52. Brown JR., et al. “Encephalitis diagnosis using metagenomics: application of next generation sequencing for undiagnosed cases”. Journal of Infectious Diseases 76 (2018): 225–240. 
53. Simner PJ., et al. “Understanding the promises and hurdles of metagenomic next-generation sequencing as a diagnostic tool for infectious diseases”. Clinical Infectious Diseases 66 (2018): 778-788. 
54. Wilson MR., et al. “Diagnosing Balamuthia mandrillaris encephalitis with metagenomic deep sequencing”. Annals of Neurology 78 (2015): 722–730. 
55. Michael BD., et al. “The interleukin-1 balance during encephalitis is associated with clinical severity,blood-brain barrier permeability, neuroimaging changes,and disease outcome”. The Journal of Infectious Diseases 213 (2016): 1651–1660. 
56. Griffiths MJ., et al. “In enterovirus 71 encephalitis with cardio-respiratory compromise, elevated interleukin 1β, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis”. The Journal of Infectious Diseases 206 (2012): 881–892. 
57. Bastos MS., et al. “Divergent cerebrospinal fluid cytokine network induced by non-viral and different viral infections on the central nervous system”. BMC Infectious Diseases 15 (2015): 345. 
58. Kothur K., et al. “Utility of CSF cytokine/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis”. PLoS One 11.8 (2016): e0161656. 
59. Whitley RJ., et al. “Vidarabine versus acyclovir therapy in herpes simplex encephalitis”. The New England Journal of Medicine 314 (1986): 144–149. 
60. Kimberlin DW., et al. “Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections”. Pediatrics 108 (2001): 230-238. 
61. Maraş Genç H., et al. “Clinical outcomes in children with herpes simplex encephalitis receiving steroid therapy”. Journal of Clinical Virology 80 (2016): 87-92. 
62. Ramos-Estebanez C., et al. “A systematic review on the role of adjunctive corticosteroids in herpes simplex virus encephalitis: is timing critical for safety and efficacy?”. Antiviral Therapy 19 (2014): 133-139. 
63. Venkatesan A. “Epidemiology and outcomes of acute encephalitis”. Current Opinion in Neurology 28 (2015): 277–282. 
64. Leibovitch EC and Jacobson S. “Vaccinations for neuroinfectious disease: a global health priority”. Neurotherapeutics 13 (2016): 562-570. 
65. Upreti SR., et al. “Updated estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal”. PLOS Neglected Tropical Diseases 11.9 (2017): e0005866. 
66. Streng A., et al. “Decline of neurologic varicella complications in children during the first seven years after introduction of universal varicella vaccination in Germany, 2005-2011”. The Pediatric Infectious Disease Journal 36 (2017): 79-86. 
67. Salimi H., et al. “Encephalitic arboviruses: emergence, clinical presentation, and neuropathogenesis”. Neurotherapeutics 13 (2016): 514-534. 
68. Olsen SJ., et al. “Infectious causes of encephalitis and meningoencephalitis in Thailand, 2003-2005”. Emerging Infectious Diseases Journal 21.2 (2015): 280–289. 
69. Venkatesan A., et al. “Acute encephalitis in immunocompetent adults”. Lancet 393.10172 (2019): 702–716.
70. Xu Y., et al. “Characterization of inflammatory cytokine profiles in cerebrospinal fluid of hand, foot, and mouth disease children with enterovirus 71-related encephalitis in Hangzhou, Zhejiang, China”. Medicine. 98.52 (2019): e18464. 
71. Tansarli GS and Chapin KC. “Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis”. Clinical Microbiology and Infection (2019).
72. Zhao WL., et al. Zhonghua Yi Xue Za Zhi. 98.15 (2018): 1152–1157. 
73. Hu Z., et al. “Metagenomic next-generation sequencing as a diagnostic tool for toxoplasmic encephalitis”. Annals of Clinical Microbiology and Antimicrobials 17.1 (2018): 45. 
74. Liu LL., et al. “Next-generation sequencing technology as a powerful detection and semi-quantitative method for herpes simplex virus type 1 in pediatric encephalitis”. Journal of NeuroVirology (2019). 
75. Kennedy PGE., et al. “Viral Encephalitis of Unknown Cause: Current Perspective and Recent Advances”. Viruses 9.6 (2017):138.

Citation

Citation: Rajib Dutta. “Acute or Subacute Infectious Encephalitis: How to Approach?". Acta Scientific Microbiology 3.3 (2020): 01-08.

Copyright

Copyright: © 2020 Rajib Dutta. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.